SOHM, a biopharmaceutical company focused on developing gene-editing technologies, has provided a progress update on its newly acquired gene editing technology, ABBIE (A Binding Based Integrase Enzyme), that precisely incorporates foreign DNA into cell genomes. The product will be commercially launched as off-the-shelf kits by Q3 2024.

ABBIE’s features include its ability to provide researchers with a way to implant specific designs of foreign DNA into the genomes of cells, thus considerably enhancing the safety and ease of genetic modifications. The system increases the efficiency of gene insertions which, in turn, reduces both costs and time dedicated to such endeavors.

California-based SOHM is a biopharmaceutical company that develops and commercializes gene-editing technologies for research, synthetic biology, and therapeutic purposes. Focusing on precision medicine, SOHM aims to offer efficient, targeted gene-editing solutions.